Affinage

RPS6KA3

Ribosomal protein S6 kinase alpha-3 · UniProt P51812

Length
740 aa
Mass
83.7 kDa
Annotated
2026-04-28
100 papers in source corpus 41 papers cited in narrative 41 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RSK2 (RPS6KA3) is a dual-kinase-domain serine/threonine kinase operating downstream of ERK1/2 MAPK signaling that integrates mitogenic, stress, and cytokine signals to regulate transcription, cell survival, cytoskeletal dynamics, exocytosis, and differentiation across diverse cell types. Its C-terminal kinase domain is maintained in an autoinhibited state by a C-terminal αL-helix; activation occurs through ERK-mediated phosphorylation (facilitated by the scaffold PEA-15) and, in the FGFR3 pathway, by direct tyrosine phosphorylation at Y529 and Y707 that disrupts this autoinhibitory element (PMID:18084304, PMID:19223461, PMID:18077417). RSK2 phosphorylates a broad substrate repertoire—including CREB, ATF4, c-Fos, Bad, IκBα, caspase-8, STAT3, T-bet, TRAF6, PLD1, stathmin, LARG, NHE3, and RLC20—thereby coupling MAPK activation to transcriptional programs (c-fos induction, NF-κB activation, IFNγ production), anti-apoptotic signaling, osteoblast differentiation, neurite outgrowth, vascular smooth muscle tone, and immune cell function (PMID:9770464, PMID:15109498, PMID:11983683, PMID:20385620, PMID:24336713, PMID:30377223, PMID:29133416). Loss-of-function mutations in RPS6KA3 cause Coffin–Lowry syndrome, an X-linked intellectual disability disorder with skeletal abnormalities (PMID:8955270).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 1996 High

    Identifying RSK2 as the Coffin–Lowry syndrome gene established that loss of a growth-factor-regulated kinase downstream of MAPK causes a syndromic intellectual disability with skeletal involvement.

    Evidence In vitro S6 kinase assay on patient-derived RSK2 mutants showing kinase inactivation

    PMID:8955270

    Open questions at the time
    • Substrate(s) mediating the skeletal and cognitive phenotypes were unknown
    • Whether kinase-dead RSK2 has dominant-negative effects was not addressed
  2. 1998 High

    Demonstrating that RSK2 is specifically required for EGF-induced CREB Ser-133 phosphorylation and c-fos transcription identified the first physiological substrate and placed RSK2 as a non-redundant CREB kinase in mitogenic signaling.

    Evidence CLS patient fibroblasts lacking RSK2, transfection rescue, promoter-reporter assay

    PMID:9770464

    Open questions at the time
    • Whether CREB phosphorylation deficiency explains the CLS phenotype was not tested
    • Stimulus specificity (EGF vs. serum) raised questions about upstream pathway selectivity
  3. 1999 High

    Biochemical identification of RSK2 as the c-Fos kinase (phosphorylating Ser362) unified two independently described kinase activities and established c-Fos as a direct RSK2 substrate in NGF-stimulated neurons.

    Evidence Affinity chromatography purification from PC12 cells, mass spectrometry, in vitro phosphorylation

    PMID:9920881

    Open questions at the time
    • Functional consequence of Ser362 phosphorylation (stabilization vs. transcriptional modulation) was not yet resolved
  4. 2000 High

    Showing that RSK2 phosphorylates myosin II regulatory light chain at Ser19 expanded RSK2's role beyond transcription to direct cytoskeletal regulation, though MAPK-mediated phosphorylation suppresses this activity, suggesting signal-dependent substrate switching.

    Evidence In vitro kinase assay with phosphopeptide mapping and S19A/T18A mutagenesis

    PMID:10965042

    Open questions at the time
    • In vivo relevance of RSK2-mediated MRLC phosphorylation was not demonstrated at this point
    • Relationship to MLCK-mediated Ser19 phosphorylation in cells was unclear
  5. 2001 High

    Discovery of the RSK2–CBP complex revealed a mutual autoinhibition mechanism in quiescent cells where mitogenic activation simultaneously releases kinase and acetyltransferase activities, coupling RSK2 to chromatin remodeling. In parallel, RSK2 was shown to phosphorylate ERα at Ser167 and allosterically activate ERα-mediated transcription, linking MAPK signaling to estrogen receptor function.

    Evidence Reciprocal Co-IP plus enzymatic activity assays and mutagenesis (RSK2–CBP); transcriptional reporter, domain mapping, pulldown (RSK2–ERα)

    PMID:11432835 PMID:11564891

    Open questions at the time
    • Whether CBP–RSK2 complex forms in vivo in tissues affected by CLS was not tested
    • The full set of ERα target genes regulated by RSK2 phosphorylation was unknown
  6. 2002 High

    Identification of Bad Ser112 as a direct RSK2 substrate in UV-induced survival signaling established RSK2 as an anti-apoptotic kinase that promotes Bad–Bcl-XL dissociation.

    Evidence In vitro kinase assay, CLS patient RSK2-deficient cells, dominant-negative mutants

    PMID:11983683

    Open questions at the time
    • Whether RSK2 is the sole kinase for Bad Ser112 in UV signaling was not resolved
    • Contribution to CLS neuropathology was not addressed
  7. 2004 High

    Genetic epistasis between Rsk2 and Atf4 knockout mice, combined with direct phosphorylation of ATF4 by RSK2, identified the RSK2–ATF4 axis as a critical driver of osteoblast differentiation and provided a molecular explanation for the skeletal phenotype of Coffin–Lowry syndrome.

    Evidence Double KO mice, in vitro kinase assay, osteoblast differentiation and gene expression assays

    PMID:15109498

    Open questions at the time
    • Specific ATF4 phosphorylation site(s) and their individual contributions were not fully mapped
    • Whether ATF4 phosphorylation also explains the cognitive phenotype was unknown
  8. 2005 High

    Demonstrating that RSK2-mediated Ser362 phosphorylation stabilizes c-Fos protein and is essential for c-Fos-driven osteosarcoma in mice linked RSK2 to oncogenesis through post-translational stabilization of a proto-oncogene.

    Evidence RSK2 KO mice crossed with c-Fos-overexpressing osteosarcoma model

    PMID:15719069

    Open questions at the time
    • Whether RSK2 contributes to human osteosarcoma was not addressed
    • Other c-Fos-stabilizing kinases were not excluded
  9. 2007 High

    Structural determination of the RSK2 C-terminal kinase domain revealed a C-terminal αL-helix autoinhibition mechanism, providing a framework for understanding how upstream signals (ERK docking, phosphorylation) activate the enzyme. Concurrently, PEA-15 was identified as a scaffold that bridges ERK to RSK2 to enhance CREB signaling, and NFAT3 was identified as a RSK2 substrate driving myoblast differentiation.

    Evidence X-ray crystallography at 2.0 Å (structure); Co-IP, PEA-15-null lymphocytes, CREB reporter (PEA-15); Co-IP, in vitro kinase assay, myotube differentiation (NFAT3)

    PMID:17213202 PMID:18077417 PMID:18084304

    Open questions at the time
    • Full-length RSK2 structure including both kinase domains was not obtained
    • How PEA-15 scaffolding is regulated in different cell types was not resolved
  10. 2008 High

    Identification of PLD1 Thr-147 as a direct RSK2 phosphorylation site controlling calcium-regulated exocytosis in chromaffin cells extended RSK2 function to vesicle trafficking and secretion.

    Evidence Co-IP, in vitro kinase assay, phosphomimetic PLD1 rescue, amperometry

    PMID:18550821

    Open questions at the time
    • Whether other RSK isoforms contribute to PLD1 regulation was not tested
    • The identity of the calcium sensor upstream of RSK2 was not determined
  11. 2009 High

    FGFR3-mediated direct tyrosine phosphorylation of RSK2 at Y529 and Y707 revealed a non-canonical activation mechanism that disrupts the autoinhibitory αL-helix and facilitates ERK docking, linking receptor tyrosine kinase signaling to RSK2 through a mechanism independent of ERK-only activation.

    Evidence In vitro kinase assay, Y529/Y707 mutagenesis, W332 linker mutant, RSK2 KO bone marrow transplant in TEL-FGFR3 disease model

    PMID:19223461

    Open questions at the time
    • Whether other RTKs tyrosine-phosphorylate RSK2 at these sites was not systematically examined
    • Structural basis of αL-helix displacement by Y707 phosphorylation was not directly visualized
  12. 2010 High

    A cluster of discoveries in 2010 greatly expanded RSK2's substrate repertoire and physiological roles: RSK2 phosphorylates IκBα (Ser32) to activate NF-κB and block TNF-α-induced apoptosis; phosphorylates caspase-8 (Thr263) triggering its ubiquitination and degradation to block Fas-induced apoptosis; is required for T-cell activation and homeostatic expansion; and participates in cortical neurogenesis by promoting radial precursor-to-neuron differentiation.

    Evidence In vitro kinase assays and phosphosite mutagenesis (IκBα, caspase-8); RSK2 KO mouse T-cell assays; in utero electroporation and shRNA in cortical precursors

    PMID:17938253 PMID:20385620 PMID:20832397 PMID:21183680

    Open questions at the time
    • How RSK2 selects among competing substrates in a given cell type is not understood
    • Whether IκBα Ser32 phosphorylation by RSK2 is redundant with IKK-mediated phosphorylation in vivo was not resolved
  13. 2013 High

    RSK2's role in neurite outgrowth was mechanistically traced to PLD1 Thr-147 phosphorylation controlling VAMP-7-dependent vesicle fusion at growth cones; simultaneously, RSK2 was shown to inhibit ASK1 by multi-site phosphorylation and to regulate FGFR1 endocytosis via Ser789 phosphorylation, revealing RSK2 as a feedback regulator of its own upstream receptor.

    Evidence In vitro kinase assay, phosphomimetic rescue, TIRF microscopy (PLD1/neurite); ASK1 ATP-binding and MKK6-binding assays with mutagenesis; yeast two-hybrid, Co-IP, FGFR1 endocytosis assay with S789A mutant

    PMID:23608533 PMID:24141780 PMID:24336713

    Open questions at the time
    • Whether RSK2–FGFR1 feedback operates in neurons to modulate CLS-relevant circuits was not tested
    • The relative contribution of each ASK1 phosphosite to survival signaling was not individually dissected in vivo
  14. 2015 High

    Identification of NHE3 Ser663 phosphorylation by RSK2 at the apical membrane linked RSK2 to epithelial ion transport, establishing RSK2 as a PDK1-dependent regulator of sodium/proton exchange.

    Evidence Co-IP, in vitro kinase assay, S663A mutagenesis, NHE3 transport activity assay, siRNA

    PMID:25855080

    Open questions at the time
    • Relevance of RSK2–NHE3 axis to systemic acid-base or blood pressure regulation was not tested in vivo
  15. 2016 High

    RSK2-mediated phosphorylation of stathmin at Ser16 was shown to stabilize microtubules at the leading edge and promote cancer cell invasion and metastasis, providing a direct mechanistic link between RSK2 and microtubule dynamics in migration.

    Evidence Co-IP, in vitro kinase assay, S16D phosphomimetic rescue, mouse metastasis model

    PMID:27041561

    Open questions at the time
    • Whether stathmin phosphorylation contributes to CLS-associated neuronal phenotypes was not addressed
  16. 2017 High

    Two studies identified RSK2 substrates in directed cell migration (LARG Ser1288 → RhoA/B activation) and immune regulation (T-bet Ser498/Ser502 → IFNγ transcription), demonstrating that RSK2 non-redundantly controls both cytoskeletal rearrangement through Rho GTPase signaling and adaptive immunity through T-bet-dependent gene expression.

    Evidence Endogenous Co-IP of RSK2–LARG–RhoA, in vitro kinase assays, phosphosite mutagenesis, cell migration assay; T-bet phosphomimetic bone marrow reconstitution in RSK2 KO mice reducing colon cancer metastasis

    PMID:29133416 PMID:29279389

    Open questions at the time
    • Whether RSK2 regulates other RhoGEFs besides LARG was not examined
    • The T-bet phosphosite contribution to other Th1 effector functions beyond IFNγ was not dissected
  17. 2018 High

    RSK2 was established as a physiological regulator of vascular tone through direct phosphorylation of RLC20 and NHE-1 in smooth muscle, and as a driver of inflammation through TRAF6 phosphorylation promoting K63 ubiquitination; additionally, ERα was shown to sequester active RSK2 in the nucleus to drive a proneoplastic program, with nuclear RSK2 alone sufficient to initiate mammary ductal carcinoma in transgenic mice.

    Evidence RSK2 KO mouse vascular physiology (dilated arteries, reduced myogenic tone); RSK2 KO colitis model with TRAF6 ubiquitination analysis; RSK2–ERα Co-IP, nuclear fractionation, transgenic mouse mammary carcinoma

    PMID:29351904 PMID:29563609 PMID:30377223

    Open questions at the time
    • Structural basis of ERα-mediated RSK2 nuclear sequestration was not determined
    • Whether vascular phenotype contributes to CLS clinical features was not investigated
  18. 2020 High

    Discovery that RSK2-inactivating mutations in hepatocellular carcinoma paradoxically upregulate MAPK signaling by disrupting a SOS1/2-dependent negative feedback loop revealed RSK2 as both an oncogenic effector and a tumor-suppressive feedback regulator depending on context.

    Evidence Exome sequencing, RSK2-null HCC cell reconstitution, RNA-seq, mass spectrometry

    PMID:32918955

    Open questions at the time
    • Whether SOS1/2 is a direct RSK2 substrate was not established
    • How RSK2 loss enhances cholesterol biosynthesis gene expression mechanistically was not resolved
  19. 2023 High

    The RSK2–RPS6 phosphorylation axis was shown to be required for conditioning-lesion-induced axon regeneration in both PNS and CNS, positioning RSK2 as a potential therapeutic target for spinal cord injury repair.

    Evidence RSK2 KO mice, DRG conditioning lesion model, dorsal column injury model, phospho-RPS6 analysis

    PMID:37068088

    Open questions at the time
    • Specific RPS6 phosphosites targeted by RSK2 in regenerating neurons were not individually validated
    • Whether RSK2 overexpression can enhance regeneration beyond baseline was not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • A full-length structure of RSK2 encompassing both kinase domains and the linker region is lacking, and the rules governing substrate selection among the many RSK2 substrates in different cell types remain undefined.
  • No full-length RSK2 structure exists
  • No systematic phosphoproteomics comparing RSK2-dependent substrates across cell types
  • Isoform-specific redundancy with RSK1/RSK3/RSK4 is poorly mapped for most substrates

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 23 GO:0098772 molecular function regulator activity 4
Localization
GO:0005634 nucleus 4 GO:0005829 cytosol 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-162582 Signal Transduction 10 R-HSA-74160 Gene expression (Transcription) 7 R-HSA-5357801 Programmed Cell Death 4 R-HSA-168256 Immune System 3 R-HSA-112316 Neuronal System 2 R-HSA-1266738 Developmental Biology 2 R-HSA-5653656 Vesicle-mediated transport 2
Partners
CBPESR1FGFR1FGFR3LARGMAPK1PEA15PLD1
Complex memberships
RSK2–CBP complexRSK2–ERK1/2 heteromeric complexRSK2–ERα complex

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 RSK2 (RPS6KA3) encodes a growth factor-regulated kinase acting downstream of the MAPK pathway; missense mutations at critical sites render RSK2 inactive in a S6 kinase assay, establishing loss-of-function as the cause of Coffin-Lowry syndrome In vitro S6 kinase assay, mutation analysis of CLS patient-derived RSK2 Nature High 8955270
1998 RSK2 is specifically required for EGF-induced phosphorylation of CREB at Ser-133 and for transcriptional induction of c-fos; cells from CLS patients lacking functional RSK2 show drastically attenuated CREB phosphorylation in response to EGF but not serum or cAMP Western blot phosphorylation analysis in CLS patient fibroblasts; transfection rescue; promoter-reporter assay Proceedings of the National Academy of Sciences of the United States of America High 9770464
2001 RSK2 and CBP form a complex in quiescent cells where both RSK2 kinase activity and CBP acetyltransferase (HAT) activity are mutually inhibited; mitogenic stimulation causes RSK2 phosphorylation at Ser227, leading to complex dissociation and concurrent activation of both RSK2 kinase and CBP HAT activities Co-immunoprecipitation, in vitro kinase assay, HAT activity assay, phosphorylation-site mutagenesis Molecular and cellular biology High 11564891
2001 RSK2 phosphorylates ERα at Ser167 and allosterically activates ERα-mediated transcription by docking to residues 326-394 of the hormone-binding domain; anti-estrogen 4-hydroxytamoxifen blocks this by masking the RSK2 docking site; activation is specific to ERα and not ERβ, and is regulated by the RSK2 N-terminal kinase domain Transcriptional reporter assay, domain mapping with deletion mutants, phosphorylation site analysis, pull-down The EMBO journal High 11432835
2004 RSK2 phosphorylates the transcription factor ATF4, which is required for osteoblast differentiation, terminal osteoblast function, osteoblast-specific gene expression, and posttranscriptional regulation of Type I collagen synthesis; Atf4 deficiency phenocopies RSK2 loss in the skeleton Genetic epistasis (Atf4-KO vs RSK2-KO mice), in vitro kinase assay, osteoblast differentiation assays, gene expression analysis Cell High 15109498
2000 RSK2 phosphorylates the regulatory light chain of myosin II (MRLC) at Ser19 (the same site as MLCK), activating actin-stimulated MgATPase activity of myosin II; MAPK-mediated phosphorylation of RSK2 suppresses this MRLC-phosphorylating activity In vitro kinase assay, phosphopeptide mapping, phosphoamino acid analysis, GST-fusion mutagenesis (S19A, T18A/S19A) Journal of biochemistry High 10965042
1999 RSK2 is the same protein as 'Fos kinase' (phosphorylates c-Fos at Ser362) and NGFI-B kinase I in nerve growth factor-stimulated PC12 cells; identified by affinity purification and mass spectrometry tryptic fragment analysis Affinity chromatography purification, mass spectrometry, substrate specificity comparison, in vitro phosphorylation The Journal of biological chemistry High 9920881
2005 RSK2 phosphorylates c-Fos at Ser362, stabilizing c-Fos protein; loss of RSK2 reduces c-Fos protein levels and impairs c-Fos-dependent osteosarcoma formation in mice, establishing RSK2-mediated c-Fos stabilization as essential for osteosarcoma development RSK2 knockout mice crossed with c-Fos-overexpressing osteosarcoma model; phosphorylation site analysis; proliferation and apoptosis assays The Journal of clinical investigation High 15719069
2002 RSK2 phosphorylates Bad at Ser112 in response to UVB radiation, promoting dissociation of Bad from Bcl-XL; RSK2-deficient cells (from a CLS patient) are defective for UVB-induced Bad Ser112 phosphorylation; active RSK2 directly phosphorylates Bad at Ser112 in vitro In vitro kinase assay with active RSK2 and Bad protein, CLS patient-derived RSK2-deficient cells, dominant-negative kinase-dead mutants, MAP kinase inhibitors The Journal of biological chemistry High 11983683
2003 RSK2 is required for UVA-induced Ser727 phosphorylation of STAT3; active RSK2 phosphorylates STAT3 immunoprecipitates in vitro and RSK2-deficient cells show defective STAT3-Ser727 phosphorylation rescued by ectopic RSK2 expression; RSK2-mediated STAT3 phosphorylation is required for basal and UVA-stimulated STAT3 transcriptional activity In vitro kinase assay, RSK2-deficient cell lines, ectopic expression rescue, reporter assay for STAT3 transcriptional activity The Journal of biological chemistry High 12562765
2007 RSK2 directly interacts with NFAT3 (N-terminal aa 1-68 and C-terminal aa 416-674 of RSK2 bind aa 261-365 of NFAT3), phosphorylates NFAT3 in vitro, and promotes NFAT3 nuclear localization and transcriptional activation; RSK2 and NFAT3 cooperate to drive C2C12 myoblast differentiation into myotubes Co-IP, in vitro kinase assay (Km determination), nuclear localization imaging, siRNA knockdown, myotube differentiation assay The Journal of biological chemistry High 17213202
2007 PEA-15 acts as a scaffold protein that independently binds both ERK and RSK2, targeting ERK to RSK2 and thereby enhancing RSK2 activation; PEA-15 increases RSK2 activity and CREB-mediated transcription in a phosphorylation-dependent manner; PEA-15-null lymphocytes show impaired RSK2 activation after phorbol ester stimulation Co-immunoprecipitation, in vitro kinase assay, CREB reporter assay, PEA-15-null lymphocytes Proceedings of the National Academy of Sciences of the United States of America High 18077417
2007 Crystal structure of the RSK2 C-terminal kinase domain at 2.0 Å resolution reveals a C-terminal autoinhibitory αL-helix embedded in the kinase scaffold determining the inactive conformation; activation is proposed to occur through displacement of the αL-helix, rearrangement of Glu500, and T-loop reorganization X-ray crystallography at 2.0 Å resolution Nature structural & molecular biology High 18084304
2008 RSK2 physically interacts with PLD1 and phosphorylates PLD1 at Thr-147 in the N-terminal phox homology domain, stimulating PLD1 activity; RSK2 is activated by calcium-induced depolarization and controls calcium-regulated exocytosis in chromaffin cells; phosphomimetic PLD1 mutants rescue exocytosis in RSK2-depleted cells Co-IP, in vitro kinase assay, RSK2 knockdown, expression of phosphomimetic PLD1 mutants, amperometry for exocytosis Proceedings of the National Academy of Sciences of the United States of America High 18550821
2009 FGFR3 directly tyrosine-phosphorylates RSK2 at Y529 (facilitating ERK binding) and Y707 (disrupting the autoinhibitory αL-helix); FGFR3 interacts with RSK2 through residue W332 in the RSK2 linker region, and this interaction is required for FGFR3-dependent RSK2 phosphorylation and activation; RSK2 genetic deficiency attenuates TEL-FGFR3-induced myeloproliferative syndrome in mice In vitro kinase assay, mutagenesis (W332 linker mutant, Y529/Y707 phospho-site mutants), Co-IP, murine bone marrow transplant with RSK2 KO cells Molecular and cellular biology High 19223461
2009 RSK2 N-terminal kinase domain (NTD) activation is required upstream for ERK-mediated activation of the C-terminal kinase domain (CTD); Val82 and Lys100 in the NTD are critical for kaempferol binding and RSK2 activity, identified by homology modeling and mutagenesis Domain-specific activation assays, homology modeling, small-molecule docking, site-directed mutagenesis Cancer research High 19435896
2010 RSK2 phosphorylates ATF1 at Ser-63, enhancing ATF1 transcriptional activity; eriodictyol binds RSK2 N-terminal kinase domain (confirmed by crystal-structure docking and pulldown assay) and specifically inhibits RSK2-ATF1 signaling In vitro kinase assay, pulldown assay, crystal structure-based docking, ATF1 reporter assay, RSK2 KO/knockdown cells The Journal of biological chemistry High 21098035
2010 RSK2 is activated by IL-2 and IL-15 in T lymphocytes; RSK2 knockout mice show delayed cell-cycle progression, lower IL-2 production, and defective homeostatic T-cell expansion; RSK2 is non-redundantly essential for T-cell activation RSK2 knockout mouse model, T-cell proliferation assays, cytokine measurement, in vivo homeostatic expansion assay Blood High 17938253
2010 RSK2 phosphorylates IκBα at Ser-32, leading to IκBα degradation, nuclear translocation of NF-κB subunits p65 and p50, and increased NF-κB transcriptional activity in the TNF-α signaling pathway; this mediates RSK2-dependent blockade of TNF-α-induced apoptosis In vitro kinase assay, phosphorylation site analysis, NF-κB reporter assay, KO/knockdown cell models FASEB journal High 20385620
2010 RSK2 phosphorylates caspase-8 at Thr-263; EGF-induced caspase-8 ubiquitination and proteasomal degradation depends on Thr-263 phosphorylation; RSK2 blocks Fas-induced apoptosis through this phosphorylation of caspase-8 In vitro kinase assay, phosphorylation site mutagenesis, ubiquitination assay, apoptosis assay The Journal of biological chemistry High 21183680
2010 Xenopus RSK2 is the predominant p90 Rsk isoform in oocytes (~120 nM), forms a heteromeric complex with p42 MAPK via sequences at the extreme C terminus of Rsk2, and can be activated in vitro by p42 MAPK to activity comparable to maximal in vivo activation Molecular cloning, quantitative immunoblotting, co-immunoprecipitation, synthetic C-terminal peptide competition, in vitro kinase reconstitution with p42 MAPK The Journal of biological chemistry High 10934212
2010 RSK2 directly phosphorylates Xenopus Cdc25C at three sites and partially activates it; combined phosphorylation by MAPK, Cdc2/cyclin B, and RSK2 is not sufficient for full Cdc25C activation, indicating additional required events GST-Cdc25C phosphorylating activity assay in Xenopus egg extracts, in vitro RSK2 kinase assay, phosphosite mapping Proceedings of the National Academy of Sciences of the United States of America High 21041626
2013 RSK2 directly binds and phosphorylates PLD1 at Thr-147, activating PLD1 to synthesize phosphatidic acid at sites of neurite growth; RSK2-dependent PLD1 activation controls vesicle fusion (TiVAMP/VAMP-7) at neurite growth sites; RSK2 KO neurons exhibit delayed neurite outgrowth phenocopied by PLD1 KO, and phosphomimetic PLD1 rescues RSK2-silenced cells In vitro kinase assay, phosphomimetic rescue, TIRF microscopy, PC12 and primary neuron knockdown The Journal of neuroscience High 24336713
2013 RSK2 inhibits ASK1 by phosphorylating S83, T1109, and T1326; phospho-T1109/T1326 inhibits ATP binding to ASK1 while phospho-S83 attenuates MKK6 binding to ASK1; RSK2 also activates CREB to upregulate antiapoptotic PTK6 and downregulate proapoptotic ING3, providing dual transcription-dependent and -independent antianoikis protection In vitro kinase assay, phosphosite mutagenesis, ATP binding assay, Co-IP (MKK6-ASK1), gene expression analysis, anoikis assay with RSK2 KD cells Molecular and cellular biology High 23608533
2015 RSK2 directly interacts with NHE3 at the apical membrane and phosphorylates NHE3 at Ser663, stimulating NHE3-mediated Na+/H+ exchange activity; LPA-induced NHE3 regulation requires PDK1-mediated RSK2 activation and is specific to RSK2 (not RSK1) Co-IP, in vitro kinase assay, phosphosite mutagenesis (S663A), NHE3 transport activity assay, siRNA knockdown American journal of physiology. Cell physiology High 25855080
2016 RSK2 directly binds stathmin and phosphorylates it at Ser16 at the leading edge of cancer cells, reducing stathmin-mediated microtubule depolymerization; phospho-mimetic stathmin S16D rescues the decreased invasive and metastatic potential caused by RSK2 knockdown in vitro and in vivo Co-IP, in vitro kinase assay, phosphomimetic mutant rescue (S16D stathmin), cell invasion assay, mouse metastasis model Oncogene High 27041561
2017 RSK2 phosphorylates LARG (leukemia-associated RhoGEF) at Ser1288, activating RhoA and RhoB (but not RhoC, Rac1, or Cdc42) to promote directed cell migration and invasion; RSK2 Thr577 phosphorylation is required for this LARG-RhoA activation module Co-IP (endogenous RSK2-LARG-RhoA), in vitro kinase assay, phosphosite mutagenesis, cell migration assay, RSK2 KO/KD cells Proceedings of the National Academy of Sciences of the United States of America High 29279389
2017 RSK2 phosphorylates T-bet at Ser498 and Ser502, promoting IFNγ gene transcription; phospho-mimetic T-bet (S498E/S502E) expressed in bone marrow restores IFNγ levels in RSK2 KO mice and reduces colon cancer metastasis In vitro kinase assay, phosphosite mutagenesis, gene expression analysis, RSK2 KO mouse model, bone marrow reconstitution Proceedings of the National Academy of Sciences of the United States of America High 29133416
2018 RSK2 phosphorylates RLC20 (regulatory myosin light chain) at Ser19 and an activating site on NHE-1, promoting smooth muscle contractility; RSK2-deficient mice show dilated resistance arteries, reduced myogenic tone, reduced RLC20 phosphorylation, attenuated NHE-1-dependent intracellular alkalinization, and lower blood pressure RSK2 knockout mouse arterial physiology, in vitro kinase assay (RLC20 Ser19), NHE-1 phosphorylation assay, intracellular pH and Ca2+ measurement Science signaling High 30377223
2018 RSK2 phosphorylates TRAF6 at Ser46, Ser47, and Ser48, promoting TRAF6 K63 ubiquitination required for inflammation signaling; RSK2 KO mice show significantly reduced TRAF6 K63 ubiquitination and attenuated colon inflammation signaling (Ikkα/β, p38, JNKs) In vitro kinase assay, Co-IP, RSK2 KO mouse colitis model, tissue immunoprecipitation for TRAF6 ubiquitination Oncogene High 29563609
2018 ERα sequesters active RSK2 into the nucleus via interaction with the RSK2 N-terminus to drive a proneoplastic transcriptional program; antiestrogens disrupt the ERα-RSK2 interaction, driving RSK2 to the cytoplasm; transgenic mice expressing nuclear-targeted RSK2 in mammary gland develop high-grade ductal carcinoma in situ Co-IP (RSK2-ERα), nuclear/cytoplasmic fractionation, transgenic mouse model, tumor metastasis assay Cancer research High 29351904
2020 RSK2-inactivating mutations in HCC attenuate a SOS1/2-dependent negative feedback loop on MAPK signaling, leading to paradoxical MAPK pathway upregulation; RSK2 loss also enhances cholesterol biosynthesis-related gene expression Exome sequencing, RSK2-null HCC cell lines, RSK2 reconstitution, RNA sequencing, mass spectrometry, in vitro/in vivo proliferation/migration assays Journal of hepatology High 32918955
2010 RSK2 is required for cortical radial precursor-to-neuron differentiation during mammalian neurogenesis; Rsk2 knockdown in murine cortical precursors causes accumulation of proliferating Pax6-positive radial precursors and decreased neurogenesis, while astrocyte generation is unaffected shRNA knockdown in cortical precursors, in utero electroporation, cell fate analysis (Pax6 staining, neuronal markers) Developmental biology High 20832397
2013 RSK2 phosphorylates VGLL1 at Ser84 downstream of TGF-β/ERK signaling; RSK2-phosphorylated VGLL1 binds TEAD4 to activate MMP9 transcription, promoting gastric cancer invasion and proliferation; VGLL1 S84A mutation abrogates TEAD4 binding and MMP9 transcription Site-directed mutagenesis, Co-IP, in vitro kinase assay (implied), ChIP, EMSA, invasion assay Biochimica et biophysica acta. Molecular cell research Medium 33069758
2001 ERK2 but not ERK1 directly phosphorylates C/EBPβ at a consensus MAPK site in vitro; p90(Rsk2) is required for Ras-stimulated C/EBPβ-SRF interaction at the c-fos SRE, placing RSK2 as a downstream mediator of ERK2 in this pathway In vitro kinase assay with recombinant C/EBPβ, dominant-negative ERK constructs, reporter assay for SRE activity The Journal of biological chemistry Medium 11500490
2006 ANG II-mediated ERK1/2 activation of RSK2 (via c-Src/Yes/Fyn signaling) leads to RSK2 nuclear translocation and SRF phosphorylation, contributing to c-fos transcription and cell proliferation; blocking c-Src/Yes/Fyn abolishes RSK2 activation and nuclear translocation Dominant-negative signaling constructs, RSK inhibitor (SL0101), RSK2 nuclear translocation measurement, proliferation assay American journal of physiology. Cell physiology Medium 16723511
2012 RSK2, downstream of MEK1-ERK cascade, stabilizes GLI2 protein by inhibiting GSK-3β-mediated phosphorylation and ubiquitination of GLI2, promoting its nuclear translocation in the Hedgehog signaling pathway Protein half-life assay (CHX chase), ubiquitination assay, nuclear translocation analysis, GLI2 phosphorylation-site deletion mutants Oncogene Medium 23208494
2013 RSK2 interacts with and phosphorylates GSK3β at Ser9, inhibiting GSK3β activity; RSK2-deficient MEFs show reduced GSK3β Ser9 phosphorylation and increased apoptosis under calcium stress, which is rescued by re-expression of RSK2 Co-IP, Western blot phosphorylation analysis, RSK2 KO and rescue MEF system, apoptosis assay Biochemical and biophysical research communications Medium 24055036
2013 RSK2 regulates FGFR1 endocytosis by phosphorylating Ser789 in the FGFR1 C-terminal tail; RSK2 inhibition or S789A mutation prolongs FGFR1 tyrosine phosphorylation and reduces FGFR1 endocytosis and ubiquitination Yeast two-hybrid (initial identification), confirmed by Co-IP in vitro and in vivo, in vitro kinase assay, phosphosite mutagenesis (S789A), FGFR1 endocytosis assay Oncogene High 24141780
2023 RSK2 phosphorylates ribosomal protein S6 (RPS6), and the RSK2-RPS6 axis is required for the preconditioning effect in DRG neurons and for both PNS and CNS axonal regeneration; RSK2 promotes spinal cord synaptic plasticity and functional recovery after injury RSK2 KO mice, DRG neuron conditioning lesion model, dorsal column injury model, phospho-RPS6 analysis PLoS biology High 37068088
2014 In FGF2/FGFR2 signaling, p38 kinase (not MEK/ERK) activates RSK2 by phosphorylating Tyr529, which facilitates phosphorylation of other RSK2 residues (Thr359/Ser363, Thr573, Ser380) and promotes mammary epithelial cell migration; RSK2 activity is indispensable for FGF2/FGFR2-mediated focal adhesion formation and cell migration Kinase inhibitor dissection (ERK, Src, p38 inhibitors), phospho-specific Western blot, FGFR2 silencing/overexpression, cell migration assay, RSK inhibitor (FMK) Biochimica et biophysica acta Medium 25014166

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 654 15109498
1996 Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature 319 8955270
1998 Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proceedings of the National Academy of Sciences of the United States of America 260 9770464
2023 The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature 132 37794185
1988 Disruption of the Escherichia coli cls gene responsible for cardiolipin synthesis. Journal of bacteriology 108 2828323
2001 Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities. Molecular and cellular biology 106 11564891
1998 Ultrastructural and temporal observations of the potyvirus cylindrical inclusions (Cls) show that the Cl protein acts transiently in aiding virus movement. Virology 93 9614878
2002 Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. The Journal of biological chemistry 84 11983683
2001 Mutations in the X-linked RSK2 gene (RPS6KA3) in patients with Coffin-Lowry syndrome. Human mutation 79 11180593
2005 Essential role of RSK2 in c-Fos-dependent osteosarcoma development. The Journal of clinical investigation 76 15719069
2006 Deletion of the Coffin-Lowry syndrome gene Rsk2 in mice is associated with impaired spatial learning and reduced control of exploratory behavior. Behavior genetics 68 17033934
2001 Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. The EMBO journal 67 11432835
2007 RSK2 mediates muscle cell differentiation through regulation of NFAT3. The Journal of biological chemistry 64 17213202
2001 ERK2- and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor. The Journal of biological chemistry 57 11500490
2015 Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway. BMC cancer 55 26253302
2010 Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation. The Journal of biological chemistry 53 21098035
2009 A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer research 53 19435896
2014 Kaempferol targets RSK2 and MSK1 to suppress UV radiation-induced skin cancer. Cancer prevention research (Philadelphia, Pa.) 51 24994661
2016 Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression. Molecular cancer research : MCR 50 27535706
2009 Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Molecular and cellular biology 50 19223461
2010 RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 47 20385620
2003 Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. The Journal of biological chemistry 47 12562765
2007 ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15. Proceedings of the National Academy of Sciences of the United States of America 46 18077417
2013 Luteolin suppresses UVB-induced photoageing by targeting JNK1 and p90 RSK2. Journal of cellular and molecular medicine 45 23551430
2001 Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation. Neurology 44 11160957
1985 Molecular cloning of the cls gene responsible for cardiolipin synthesis in Escherichia coli and phenotypic consequences of its amplification. Journal of bacteriology 44 2991193
2010 Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. The Journal of biological chemistry 42 21183680
2008 The Coffin-Lowry syndrome-associated protein RSK2 is implicated in calcium-regulated exocytosis through the regulation of PLD1. Proceedings of the National Academy of Sciences of the United States of America 42 18550821
2020 RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. Journal of hepatology 41 32918955
1999 Transcription factor phosphorylation by pp90(rsk2). Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2). The Journal of biological chemistry 41 9920881
2017 RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases. Proceedings of the National Academy of Sciences of the United States of America 40 29279389
2013 The Coffin-Lowry syndrome-associated protein RSK2 regulates neurite outgrowth through phosphorylation of phospholipase D1 (PLD1) and synthesis of phosphatidic acid. The Journal of neuroscience : the official journal of the Society for Neuroscience 40 24336713
2007 Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2. Nature structural & molecular biology 40 18084304
2014 Myricetin exerts anti-proliferative, anti-invasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 38 25192723
2011 Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors. European journal of medicinal chemistry 38 21794960
2006 Identification of novel mutations in the RSK2 gene (RPS6KA3) in patients with Coffin-Lowry syndrome. Clinical genetics 38 16879200
2016 RSK2 and its binding partners in cell proliferation, transformation and cancer development. Archives of pharmacal research 36 28013489
2007 Critical role for Rsk2 in T-lymphocyte activation. Blood 34 17938253
2013 A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer. Frontiers in oncology 32 23936765
2022 EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell reports 30 36516759
2012 MEK1-RSK2 contributes to Hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination. Oncogene 30 23208494
2013 Targeting of magnolin on ERKs inhibits Ras/ERKs/RSK2-signaling-mediated neoplastic cell transformation. Carcinogenesis 29 24031026
2002 Unusual splice-site mutations in the RSK2 gene and suggestion of genetic heterogeneity in Coffin-Lowry syndrome. American journal of human genetics 29 11992250
2013 p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms. Molecular and cellular biology 28 23608533
2012 RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Molecular cancer therapeutics 28 23012246
1994 Regional localisation of a non-specific X-linked mental retardation gene (MRX19) to Xp22. American journal of medical genetics 28 7943043
2016 RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. Oncogene 27 27041561
2006 ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1. American journal of physiology. Cell physiology 27 16723511
1995 Identity of the Escherichia coli cls and nov genes. Journal of bacteriology 27 7665497
2018 Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. The Journal of international medical research 26 29896981
2016 RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget 26 27829215
2015 Regulation of NHE3 by lysophosphatidic acid is mediated by phosphorylation of NHE3 by RSK2. American journal of physiology. Cell physiology 26 25855080
2013 Defective synaptic transmission and structure in the dentate gyrus and selective fear memory impairment in the Rsk2 mutant mouse model of Coffin-Lowry syndrome. Neurobiology of disease 26 23742761
2013 RSK2 regulates endocytosis of FGF receptor 1 by phosphorylation on serine 789. Oncogene 26 24141780
2007 Altered neurodevelopment associated with mutations of RSK2: a morphometric MRI study of Coffin-Lowry syndrome. Neurogenetics 26 17318637
2018 EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO molecular medicine 25 30361264
2015 A Negative Index Metamaterial-Inspired UWB Antenna with an Integration of Complementary SRR and CLS Unit Cells for Microwave Imaging Sensor Applications. Sensors (Basel, Switzerland) 25 26007721
2000 Activation of actin-activated MgATPase activity of myosin II by phosphorylation with MAPK-activated protein kinase-1b (RSK-2). Journal of biochemistry 25 10965042
1999 Unreported RSK2 missense mutation in two male sibs with an unusually mild form of Coffin-Lowry syndrome. Journal of medical genetics 25 10528858
2017 Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma. British journal of haematology 24 28439875
2019 Isobavachalcone exerts anti‑proliferative and pro‑apoptotic effects on human liver cancer cells by targeting the ERKs/RSK2 signaling pathway. Oncology reports 23 30942462
2006 Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and nonsyndromic X-linked mental retardation. Clinical genetics 23 17100996
2003 Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2) causing Coffin-Lowry syndrome. Clinical genetics 23 14986828
2000 Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs. The Journal of biological chemistry 23 10934212
2018 Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2. Oncotarget 22 30344937
2010 Coffin-Lowry syndrome: a role for RSK2 in mammalian neurogenesis. Developmental biology 22 20832397
2013 RSK2-induced stress tolerance enhances cell survival signals mediated by inhibition of GSK3β activity. Biochemical and biophysical research communications 21 24055036
2010 Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proceedings of the National Academy of Sciences of the United States of America 21 21041626
2003 Expression pattern of the Rsk2, Rsk4 and Pdk1 genes during murine embryogenesis. Gene expression patterns : GEP 21 12711546
1999 Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS). European journal of human genetics : EJHG 21 10094187
1997 Complement Cls, a classical enzyme with novel functions at the endochondral ossification center: immunohistochemical staining of activated Cls with a neoantigen-specific antibody. Cell and tissue research 21 9134868
2020 Microbial cell lysate supernatant (CLS) alteration impact on platinum nanoparticles fabrication, characterization, antioxidant and antibacterial activity. Materials science & engineering. C, Materials for biological applications 20 32919653
2020 VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling. Biochimica et biophysica acta. Molecular cell research 20 33069758
2014 RSK2 is a modulator of craniofacial development. PloS one 20 24416220
2014 Rsk2 controls synovial fibroblast hyperplasia and the course of arthritis. Annals of the rheumatic diseases 20 25414238
2007 Involvement of ERKs, RSK2 and PKR in UVA-induced signal transduction toward phosphorylation of eIF2alpha (Ser(51)). Carcinogenesis 20 17404396
2002 X-linked Coffin-Lowry syndrome (CLS, MIM 303600, RPS6KA3 gene, protein product known under various names: pp90(rsk2), RSK2, ISPK, MAPKAP1). European journal of human genetics : EJHG 20 11896450
2014 Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration. Biochimica et biophysica acta 19 25014166
2014 RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood 19 25395420
2007 Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling. Journal of neurochemistry 19 17663748
2023 RSK1 and RSK2 serine/threonine kinases regulate different transcription programs in cancer. Frontiers in cell and developmental biology 18 36684450
2018 RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation. Oncogene 18 29563609
2016 Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways. International journal of oncology 18 27082640
2018 ERα-Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis. Cancer research 17 29351904
2018 RSK2 contributes to myogenic vasoconstriction of resistance arteries by activating smooth muscle myosin and the Na+/H+ exchanger. Science signaling 17 30377223
2014 Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2. Journal of virology 17 24719417
2014 The historical Coffin-Lowry syndrome family revisited: identification of two novel mutations of RPS6KA3 in three male patients. American journal of medical genetics. Part A 17 25044551
2010 Transcriptome profile reveals AMPA receptor dysfunction in the hippocampus of the Rsk2-knockout mice, an animal model of Coffin-Lowry syndrome. Human genetics 17 21116650
2006 A novel RSK2 (RPS6KA3) gene mutation associated with abnormal brain MRI findings in a family with Coffin-Lowry syndrome. American journal of medical genetics. Part A 17 16691578
2023 The RSK2-RPS6 axis promotes axonal regeneration in the peripheral and central nervous systems. PLoS biology 16 37068088
2022 New Mutations in cls Lead to Daptomycin Resistance in a Clinical Vancomycin- and Daptomycin-Resistant Enterococcus faecium Strain. Frontiers in microbiology 16 35801099
2022 CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway. Journal of experimental & clinical cancer research : CR 16 35964097
2021 Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer. Oncology letters 16 33574926
2021 Therapeutic Effect of Idebenone on Rats with Vascular Dementia via the MicroRNA-216a/RSK2/NF-κB Axis. Neuropsychiatric disease and treatment 16 33628024
2017 RSK2 phosphorylates T-bet to attenuate colon cancer metastasis and growth. Proceedings of the National Academy of Sciences of the United States of America 16 29133416
2012 The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. European journal of cancer (Oxford, England : 1990) 16 23041051
1997 Cytokine-mediated erythroid maturation in megakaryoblastic human cell line HU-3. Experimental hematology 16 9406997
2021 The Volatilomic Footprints of Human HGC-27 and CLS-145 Gastric Cancer Cell Lines. Frontiers in molecular biosciences 15 33585559
2018 Gossypin inhibits gastric cancer growth by direct targeting of AURKA and RSK2. Phytotherapy research : PTR 15 30536456
2014 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors. Bioorganic & medicinal chemistry letters 15 24534486